Navigating ‘k-land’: a qualitative exploration of participants’ experiences of ketamine-assisted psychotherapy for methamphetamine use disorder - Report - MDSpire

Navigating ‘k-land’: a qualitative exploration of participants’ experiences of ketamine-assisted psychotherapy for methamphetamine use disorder

  • By

  • Kathryn Fletcher

  • Nadine Ezard

  • Krista J. Siefried

  • Sophie van der Helder

  • Jack Freestone

  • Jonathan Brett

  • Robert May

  • Liam Acheson

  • Brendan Clifford

  • June 24, 2026

  • 0 min

Share

Clinical Report: Exploring Experiences of Ketamine-Assisted Psychotherapy

Overview

This qualitative study investigates the experiences of individuals with methamphetamine use disorder undergoing ketamine-assisted psychotherapy. Findings reveal that participants experienced a temporary state of 'psychological space' that facilitated engagement with psychotherapy.

Background

Methamphetamine use disorder (MAUD) poses significant psychiatric and physical health challenges, with limited treatment options available. Ketamine-assisted psychotherapy (KAP) has emerged as a potential intervention, yet understanding the subjective experiences of individuals undergoing this treatment is crucial for optimizing therapeutic approaches.

Data Highlights

No numerical data available in the source material.

Key Findings

  • Participants reported prior treatment experiences with limited sustained benefit, leading to openness towards KAP.
  • A supportive clinical environment was essential for fostering relational safety and engagement.
  • Ketamine sessions induced altered states characterized by reduced emotional and cognitive reactivity.
  • Behavioral changes in methamphetamine use were variable and dependent on ongoing therapeutic engagement and personal motivation.
  • Participants expressed uncertainty about whether changes were due to ketamine, psychotherapy, or contextual factors.

Clinical Implications

The findings indicate that KAP for MAUD is a context-dependent process that requires integration of pharmacological and psychotherapeutic elements.

Conclusion

KAP for MAUD is experienced as a multi-stage process, highlighting the interaction of pharmacological, psychotherapeutic, and contextual factors.

Related Resources & Content

  1. BMC Psychiatry, 2025 -- Cortical morphological alterations in methamphetamine-induced psychosis: a surface-based morphometry study
  2. JAMA Network Open, 2024 -- Pilot Results for Psilocybin-Assisted Psychotherapy for Cocaine Use Disorder—A Critical Appraisal
  3. Frontiers in Psychiatry, 2026 -- Rapid reduction of suicidal ideation with transient dissociative and “drunken gait” symptoms after intranasal esketamine, with music intervention: a case report
  4. JAMA Psychiatry, 2024 -- Mirtazapine for Methamphetamine Use Disorder: A Randomized Clinical Trial
  5. ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder, 2024
  6. Addiction, 2024 -- Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT‐2 trial
  7. PMC -- Protocol of an open-label safety and feasibility pilot study of ketamine-assisted psychotherapy for methamphetamine use disorder (the KAPPA trial)
  8. https://downloads.asam.org/sitefinity-production-blobs/docs/default-source/quality-science/stud_guideline_document_final.pdf
  9. Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT‐2 trial - Li - 2024 - Addiction - Wiley Online Library
  10. Protocol of an open-label safety and feasibility pilot study of ketamine-assisted psychotherapy for methamphetamine use disorder (the KAPPA trial) - PMC

Original Source(s)

Related Content